2C-D
| Clinical data | |
|---|---|
| Other names | 2,5-Dimethoxy-4-methyl-phenethylamine; 4-Methyl-2,5-dimethoxyphenethylamine; 2C-M; LE-25; LE25 | 
| Routes of administration | Oral | 
| Drug class | Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen | 
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Duration of action | 4–6 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H17NO2 | 
| Molar mass | 195.262 g·mol−1 | 
| 3D model (JSmol) | |
| Melting point | 213 to 214 °C (415 to 417 °F) (hydrochloride) | 
| 
 | |
| 
 | |
| (what is this?) (verify) | |
2C-D, also known as 2C-M or as 2,5-dimethoxy-4-methylphenethylamine, is a psychedelic drug of the 2C family that is sometimes used as an entheogen. It was first synthesized in 1970 by a team from the Texas Research Institute of Mental Sciences, and its activity was subsequently investigated in humans by Alexander Shulgin.